Alvotech (ALVO) to Release Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is expected to announce its Q2 2026 results after the market closes on Wednesday, August 19th. Analysts expect Alvotech to announce earnings of ($0.0526) per share and revenue of $103.0040 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:00 AM ET.

Alvotech Stock Performance

Shares of ALVO opened at $4.05 on Monday. The company has a market cap of $1.22 billion, a PE ratio of -16.20 and a beta of 0.18. The stock has a 50-day moving average price of $3.67 and a 200-day moving average price of $3.78. Alvotech has a 12-month low of $2.94 and a 12-month high of $9.25.

Analyst Ratings Changes

Several equities research analysts have issued reports on ALVO shares. Weiss Ratings lowered shares of Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Evercore assumed coverage on shares of Alvotech in a research report on Friday. They set an “outperform” rating on the stock. Finally, Wall Street Zen downgraded shares of Alvotech from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Alvotech presently has an average rating of “Hold” and an average price target of $7.60.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its stake in shares of Alvotech by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 36,444 shares of the company’s stock valued at $352,000 after purchasing an additional 10,573 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Alvotech by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 230,291 shares of the company’s stock valued at $2,100,000 after acquiring an additional 1,574 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Alvotech by 37.3% in the 2nd quarter. Invesco Ltd. now owns 32,398 shares of the company’s stock valued at $295,000 after acquiring an additional 8,794 shares during the last quarter. Bank of America Corp DE boosted its holdings in Alvotech by 218.0% during the 2nd quarter. Bank of America Corp DE now owns 16,623 shares of the company’s stock valued at $152,000 after acquiring an additional 11,395 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC purchased a new stake in Alvotech during the 2nd quarter valued at about $1,782,000.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high?quality, cost?effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in?house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).